Symptoms and General Pathology

All Conditions

Skin and Connective Tissue Diseases

Immune System Diseases

Necrosis

Lupus Erythematosus, Systemic

Connective Tissue Diseases

Autoimmune Diseases

All Drugs and Chemicals

Antineoplastic Agents

Antirheumatic Agents

Belimumab

Interleukin-4

No intervention. Peripheral blood and urine samples will be obtained

Francisca González- Escribano, PhD

Clara Rosso-Fernández, MD-PhD

This project is intended to identify the routes on which BAFF and APRIL act in order to detect possible future candidates to Belimumab treatment among patients diagnosed of SLE.

DESIGN Establish the influence of certain polymorphisms in the levels of expression of different transcripts and proteins.

Quantify the levels of B cell activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) in serum and urine of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA). BAFF Determine the expression levels of different BAFF and APRIL transcripts in peripheral blood mononuclear cells from patients and controls using a digital PCR (polymerase chain reaction) system.

Compare distribution of gene polymorphisms in BAFF and APRIL in patients and controls. by sequencing the exome of the ligand and receptor genes using next generation sequencing (NGS).

Correlate the transcript and protein levels with clinical manifestations and disease activity.

The results of the quantification of anti- double-stranded deoxyribonucleic acid.(dsDNA) antibody levels tests will be recorded together with those demographics, clinical-epidemiological and response to the treatment.data.

BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE

B Cell Activating Factor Belonging to the TNF (Tumor Necrosis Factor) Family (BAFF) and a Proliferation-inducing Ligand (APRIL) in Patients With Systemic Lupus Erythematosus: Investigating Biomarkers for the Response to the Belimumab Treatment

Sharing the data collected and analysed with the scientific community by publication

Quantify physiological parameters (levels of BAFF and APRIL) in serum and urine of patients and controls by ELISA.

Determine the expression levels of different physiological parameters (BAFF and APRIL transcripts) in peripheral blood mononuclear cells from patients and controls.

Quantify anti-dsDNA levels recording clinical symptoms and SLE-DAI (Systemic Lupus Erythematosus Disease Activity Index)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE	NCT03919643	Systemic Lupus ... BAFF Polymorphi...		18 Years - 60 Years	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE	NCT03919643	Systemic Lupus ... BAFF Polymorphi...		18 Years - 60 Years	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Spots Global Cancer Trial Database for baff polymorphism